EXCEED THE SPACE PROVIDED. The Division of Substance Abuse (DSA), Department of Psychiatry at Yale University School of Medicine requests a 5 year renewalperiod for its post-doctoral Drug Abuse Clinical ResearchTraining Program (CRTP) to support a total of 4 physicians and Ph.D. psychologists per year. Post-doctoral trainees will spend two to three years at Yale to obtain clinical and research training while being mentored by faculty investigators whose interests range from molecular neurobiology and genetics to pharmacologic and behavioral treatments and psychiatric epidemiology and health services research. With over 30 externally funded research projects and 28 full-time faculty, the central theme of our research program is the development and evaluation of innovative pharmacologic and behavioral treatments for substance abusers. Our multi-disciplinary program enables us to conduct research that moves rapidly and in both directions from preclinical projects ('bench') to clinical studies ('bedside'and 'community'). The overall success of the program is evidenced by the high proportion of trainees continuing in academic and clinical research careers after program completion and their publication record and continued involvement in NIH-funded clinical research. Changes implemented over the past two years and proposed in this application further strengthen the program. The main purpose of the CRTP is to provide post-doctoral trainees the opportunity to devote virtually full-time effort during the initial phase of their careers to developing the skills and experience needed to becomeindependent drug abuse clinical researchers and clinician scientists. Prospective trainees will identify a faculty mentor and develop a proposed training plan as part of the application procedure. During the training program, trainees participate in seminars on drug abuse clinical research and treatment, biostatistics and research design, and responsible conduct of scientific research. Under the supervisionof a faculty mentor, trainees gain experience in all aspects of clinical research, from initial project conceptualization and design, through study implementation, data analysis and manuscript preparation. Beginning early in the first year of the program, each trainee is expected to develop, implement and complete all phases of an independent research project, which serves as a base for future drug abuse clinical research. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
5T32DA007238-15
Application #
6935317
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Czechowicz, Dorynne D
Project Start
1988-07-01
Project End
2006-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
15
Fiscal Year
2005
Total Cost
$181,435
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Verplaetse, Terril L; Moore, Kelly E; Pittman, Brian P et al. (2018) Intersection of stress and gender in association with transitions in past year DSM-5 substance use disorder diagnoses in the United States. Chronic Stress (Thousand Oaks) 2:
Roberts, Walter; Shi, Julia M; Tetrault, Jeanette M et al. (2018) Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study. J Addict Med 12:227-233
Arout, Caroline A; Sofuoglu, Mehmet; Bastian, Lori A et al. (2018) Gender Differences in the Prevalence of Fibromyalgia and in Concomitant Medical and Psychiatric Disorders: A National Veterans Health Administration Study. J Womens Health (Larchmt) 27:1035-1044
Peltier, MacKenzie R; Sofuoglu, Mehmet (2018) Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review. CNS Drugs :
Roberts, Walter; Verplaetse, Terril L; Moore, Kelly E et al. (2018) A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco-deprived and -satiated smokers. Hum Psychopharmacol 33:e2660
Verplaetse, Terril L; Weinberger, Andrea H; Ashare, Rebecca L et al. (2018) Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. J Psychopharmacol 32:1003-1009
Roberts, Walter; Ralevski, Elizabeth; Verplaetse, Terril L et al. (2018) Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. J Subst Abuse Treat 94:91-96
Roberts, Walter; Moore, Kelly E; Peltier, MacKenzie R et al. (2018) Electronic Cigarette Use and Risk of Harmful Alcohol Consumption in the U.S. Population. Alcohol Clin Exp Res 42:2385-2393
Roberts, Walter; McKee, Sherry A (2018) Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes. Exp Clin Psychopharmacol 26:49-57
Peltier, MacKenzie R; Roys, Melanie R; Waters, Aaron F et al. (2018) Motivation and readiness for tobacco cessation among nicotine dependent postmenopausal females: A pilot study. Exp Clin Psychopharmacol 26:125-131

Showing the most recent 10 out of 130 publications